STOCK TITAN
  1. Home
  2. News
  3. NGM

Ngm Biopharmaceuticals Inc - NGM STOCK NEWS

Welcome to our dedicated news page for Ngm Biopharmaceuticals (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ngm Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ngm Biopharmaceuticals's position in the market.

News
NGM Bio Announces Closing of Tender Offer
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. has been acquired by Atlas Neon Parent, Inc., an affiliate of The Column Group, LP, through a successful cash tender offer at $1.55 per share. The acquisition resulted in NGM Bio becoming a privately held subsidiary of Parent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
Rhea-AI Summary
NGM Biopharmaceuticals announces presentation of NGM707 clinical data at AACR Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences clinical trial
-
News
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. provided updates on ongoing trials for NGM707 in colorectal cancer, NGM120 for hyperemesis gravidarum, and aldafermin for primary sclerosing cholangitis. The company reported $144.2 million in cash and announced a merger agreement with Atlas Neon Parent, Inc. Key financial results for the fourth quarter and full year 2023 were also disclosed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
Rhea-AI Summary
NGM Bio announced a definitive Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, offering $1.55 per share in cash, an 80% premium over the closing share price. The acquisition, valued at $135 million, involves a cash tender offer for all outstanding shares not held by affiliates of The Column Group, LP. The transaction is recommended by a Special Committee of independent directors and is expected to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.16%
Tags
acquisition
-
News
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. announced CEO David J. Woodhouse will participate in a panel on oncology targets at the Cowen 44th Annual Health Care Conference. The event will be webcast live and available for replay on NGM Bio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.25%
Tags
conferences
-
News
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) announced CEO and CFO participation in the B. Riley Securities 4th Annual Oncology Conference. They will provide a business update on NGM Bio’s oncology portfolio. The presentation will be available for replay on NGM Bio’s website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
News
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) announces encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab) and outlines its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
clinical trial
-
News
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) shared positive results from its Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated cirrhosis due to NASH. The trial met its primary endpoint, showing a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment. Dose-dependent improvements were reported across histologic and non-invasive secondary endpoints. The study also demonstrated that aldafermin treatment up to one year was generally well tolerated with no treatment-related serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
clinical trial
-
News
NGM Bio to Participate in Upcoming Investor Conferences
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) Announces CEO Participation in Evercore ISI HealthCONx Conference and Jefferies London Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
News
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Rhea-AI Summary
NGM Biopharmaceuticals reports $166.0 million in cash as of September 30, 2023, with expected cash runway into mid-2025. Jean-Frédéric Viret appointed as CFO. Progress made on myeloid checkpoint solid tumor programs. Data from Phase 2b trial of aldafermin selected for oral presentation at AASLD The Liver Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
earnings
Stock NGM logo
Ngm Biopharmaceuticals Inc

Nasdaq:NGM

NGM Rankings

N/A Ranked by Market Cap
#5406 Ranked by Stock Gains
N/A Ranked by Dividends

NGM Stock Data

128.53M
28.89M
21.08%
54.16%
2.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About NGM

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work